SG11201805494WA - Mutated von willebrand factor - Google Patents
Mutated von willebrand factorInfo
- Publication number
- SG11201805494WA SG11201805494WA SG11201805494WA SG11201805494WA SG11201805494WA SG 11201805494W A SG11201805494W A SG 11201805494WA SG 11201805494W A SG11201805494W A SG 11201805494WA SG 11201805494W A SG11201805494W A SG 11201805494WA SG 11201805494W A SG11201805494W A SG 11201805494WA
- Authority
- SG
- Singapore
- Prior art keywords
- parkville
- victoria
- international
- road
- csl limited
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011101011111101111101111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/117630 Al 13 July 2017 (13.07.2017) WI P0 I P CT (51) International Patent Classification: (74) Agent: DAVIS COLLISON CAVE; 1 Nicholson Street, CO7K 14/745 (2006.01) A61P 7/04 (2006.01) Melbourne, Victoria 3000 (AU). A61K 38/36 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind PCT/AU2017/050009 AO, BZ, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 6 January 2017 (06.01.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (26) Publication Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, 2016900033 7 January 2016 (07.01.2016) AU TH, ZA, ZM, ZW. RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant: CSL LIMITED [AU/AU]; 45 Poplar Road, Parkville, Victoria 3052 (AU). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: ANDREWS, Arna; C/- CSL Limited, 45 Pop- GM, lar Road, Parkville, Victoria 3052 (AU). PANOUSIS, TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, — Kosta; C/- CSL Limited, 45 Poplar Road, Parkville, Vic- TJ, toria 3052 (AU). EMMRICH, Kerstin; C/- CSL Limited, DK, 45 Poplar Road, Parkville, Victoria 3052 (AU). WILSON, LV, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — _ Michael; C/- CSL Limited, 45 Poplar Road, Parkville, SM, Victoria 3052 (AU). DOWER, Steve; C/- CSL Limited, 45 GW, KM, ML, MR, NE, SN, TD, TG). Poplar Road, Parkville, Victoria 3052 (AU). HARDY, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Mathew; C/- CSL Limited, 45 Poplar Road, Parkville, Published: . Victoria 3052 (AU). HARTMAN, Dallas; C/- CSL Lim- — with ited, 45 Poplar Road, Parkville, Victoria 3052 (AU). — with international search report (Art. 21(3)) sequence listing part of description (Rule 5.2(a)) = = = = = = = = = 1-1 © M IN 1-1 1-1 IN 1-1 (54) Title: MUTATED VON WILLEBRAND FACTOR 0 ei (57) : The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises en. ) a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the ,7 1 1 . 9 group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016900033A AU2016900033A0 (en) | 2016-01-07 | Mutated von willebrand factor | |
PCT/AU2017/050009 WO2017117630A1 (en) | 2016-01-07 | 2017-01-06 | Mutated von willebrand factor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805494WA true SG11201805494WA (en) | 2018-07-30 |
Family
ID=59273072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912857XA SG10201912857XA (en) | 2016-01-07 | 2017-01-06 | Mutated von willebrand factor |
SG11201805494WA SG11201805494WA (en) | 2016-01-07 | 2017-01-06 | Mutated von willebrand factor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912857XA SG10201912857XA (en) | 2016-01-07 | 2017-01-06 | Mutated von willebrand factor |
Country Status (14)
Country | Link |
---|---|
US (1) | US10808023B2 (en) |
EP (1) | EP3400238B1 (en) |
JP (1) | JP6755318B2 (en) |
KR (1) | KR20180098404A (en) |
CN (1) | CN108779165B (en) |
AU (1) | AU2017205776B2 (en) |
BR (1) | BR112018013822A2 (en) |
CA (1) | CA3008448A1 (en) |
DK (1) | DK3400238T3 (en) |
ES (1) | ES2881701T3 (en) |
MX (1) | MX2018008293A (en) |
RU (1) | RU2018128613A (en) |
SG (2) | SG10201912857XA (en) |
WO (1) | WO2017117630A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
DK3538133T3 (en) * | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR THE TREATMENT OF HEMOPHILIA |
JP2020530436A (en) | 2017-06-22 | 2020-10-22 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Regulation of FVIII immunogenicity by truncated VWF |
JP2021523878A (en) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | How to treat hemophilia A |
KR20220029733A (en) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII |
JP2023500953A (en) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Polypeptides for inducing tolerance to factor VIII |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
FR2673632A1 (en) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
DE4435485C1 (en) | 1994-10-04 | 1996-03-21 | Immuno Ag | Process for obtaining high-purity von Willebrand factor |
CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
WO1997040145A1 (en) | 1996-04-24 | 1997-10-30 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
US6767707B2 (en) * | 1996-07-19 | 2004-07-27 | University Of Michigan | DNA encoding canine von willebrand factor and methods of use |
PT1079805E (en) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
JP2005518181A (en) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
ES2331909T3 (en) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | FACTOR VIII STABILIZED WITH GENETICALLY MODIFIED DISULFIDE LINKS. |
WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
WO2003093313A2 (en) | 2002-04-29 | 2003-11-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
CN1767857A (en) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | Polymer-factor VIII moiety conjugates |
EP2298347B1 (en) | 2003-05-06 | 2015-09-30 | Biogen Hemophilia Inc. | Clotting factor chimeric proteins for treatment of a hemostatic disorder |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
CN1802386B (en) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | GLP-1 analog fusion proteins |
DK1699821T3 (en) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
WO2006031524A2 (en) * | 2004-09-10 | 2006-03-23 | The Regents Of The Unversity Of Colorado | Early detection of hemangiosarcoma and angiosarcoma |
WO2006053299A2 (en) | 2004-11-12 | 2006-05-18 | Bayer Healthcare Llc | Site-directed modification of fviii |
ES2434035T3 (en) | 2004-12-27 | 2013-12-13 | Baxter International Inc. | Polymer-von Willebrand factor conjugates |
CA2604299A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
PL3896090T3 (en) | 2006-06-14 | 2022-05-02 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2008005290A2 (en) * | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
WO2009054996A2 (en) * | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
KR20100095441A (en) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | Modified recombinant factor viii and von willebrand factor and methods of use |
KR101648734B1 (en) * | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
JP5876416B2 (en) * | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. | Von Willebrand factor (vWF) containing preparations and related methods, kits and uses |
EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
US20130347134A1 (en) * | 2012-06-21 | 2013-12-26 | Thomas Diacovo | Transgenic von willebrand factor animals and uses thereof |
DK3164150T3 (en) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | MODIFIED BY WILLEBRAND FACTOR |
US10663608B2 (en) * | 2015-09-21 | 2020-05-26 | Shanghai United Imaging Healthcare Co., Ltd. | System and method for calibrating a PET scanner |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
-
2017
- 2017-01-06 SG SG10201912857XA patent/SG10201912857XA/en unknown
- 2017-01-06 KR KR1020187022664A patent/KR20180098404A/en unknown
- 2017-01-06 WO PCT/AU2017/050009 patent/WO2017117630A1/en active Application Filing
- 2017-01-06 MX MX2018008293A patent/MX2018008293A/en unknown
- 2017-01-06 RU RU2018128613A patent/RU2018128613A/en not_active Application Discontinuation
- 2017-01-06 DK DK17735768.8T patent/DK3400238T3/en active
- 2017-01-06 SG SG11201805494WA patent/SG11201805494WA/en unknown
- 2017-01-06 BR BR112018013822A patent/BR112018013822A2/en not_active Application Discontinuation
- 2017-01-06 ES ES17735768T patent/ES2881701T3/en active Active
- 2017-01-06 CN CN201780005626.3A patent/CN108779165B/en active Active
- 2017-01-06 AU AU2017205776A patent/AU2017205776B2/en active Active
- 2017-01-06 US US16/068,157 patent/US10808023B2/en active Active
- 2017-01-06 CA CA3008448A patent/CA3008448A1/en active Pending
- 2017-01-06 EP EP17735768.8A patent/EP3400238B1/en active Active
- 2017-01-06 JP JP2018535384A patent/JP6755318B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20190016784A1 (en) | 2019-01-17 |
EP3400238B1 (en) | 2021-05-19 |
RU2018128613A (en) | 2020-02-07 |
EP3400238A4 (en) | 2019-07-10 |
WO2017117630A1 (en) | 2017-07-13 |
MX2018008293A (en) | 2018-09-21 |
JP6755318B2 (en) | 2020-09-16 |
JP2019504621A (en) | 2019-02-21 |
WO2017117630A9 (en) | 2018-03-29 |
EP3400238A1 (en) | 2018-11-14 |
DK3400238T3 (en) | 2021-07-26 |
ES2881701T3 (en) | 2021-11-30 |
AU2017205776B2 (en) | 2020-09-10 |
AU2017205776A1 (en) | 2018-07-05 |
KR20180098404A (en) | 2018-09-03 |
BR112018013822A2 (en) | 2018-12-11 |
CN108779165A (en) | 2018-11-09 |
SG10201912857XA (en) | 2020-02-27 |
US10808023B2 (en) | 2020-10-20 |
CA3008448A1 (en) | 2017-07-13 |
CN108779165B (en) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805497QA (en) | Mutated truncated von willebrand factor | |
SG11201805494WA (en) | Mutated von willebrand factor | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201807025SA (en) | Crispr/cas systems for c-1 fixing bacteria | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201806398YA (en) | Optimized factor viii genes | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201908918WA (en) | Novel pyridazinone herbicides |